Filter posts

WSJ: Drug Importation is “Impractical, Unsafe and Unlikely” to Lower Prices

This week, Editorial Board writers for The Wall Street Journal examined a policy proposal in …

Greenwood: In Pharma Value Chain, PBMs Manage to Benefit

Writing for The Hill, BIO’s President and CEO Jim Greenwood offered praise to the Senate Finance …

Oncologist Warns of IPI’s Potentially Dangerous Implications

Writing for Morning Consult, Dr. Lucy Langer, a clinical oncologist with Compass Oncology in Portland, …

Peter Pitts Examines the Role of PBMs and their Deceptive Tactics

A piece by Peter J. Pitts, a former FDA Associate Commissioner and President of the …

Vaccines Work: the Proof Is in the Data.

At the latest meeting of the Advisory Committee on Immunization Practices (ACIP), more than 80 …

Kentucky Officials Expose PBMs for Gaming the System

While many were watching the drug pricing debate unfold on Capitol Hill, the Kentucky Cabinet …

Two New Infographics Illustrate the Success of the Orphan Drug Act

In recognition of Rare Disease Day, BIO’s Jim Greenwood shared commentary on LinkedIn celebrating the …

Policy Outlook—How Could the Trump Administration’s Drug Reimbursement Proposals Affect Medical ...

In his State of the Union address, President Trump called on Congress to “do more” …

Market Outlook—Leveraging Market Corrections for M&A or IPOs

After a multi-year expansion of company formation and in biopharma valuations, 2018 was a year …

New BIO Report on Impact of Sarbanes-Oxley 404(b) on Emerging Biotech Innovators

BIO is out with a new report illustrating the negative impact of Sarbanes-Oxley 404(b) on …